ライフサイエンスコーパス: menstrual

1 function (evaluated by yearly assessment of menstrual activity and defined as resumed by the occurre

2 -MRS) in preterm infants with advancing post-menstrual age (PMA) and brain injury during ex-utero thi

3 nt development of BPD or PH at 36 weeks post-menstrual age (PMA) is unknown.

4 Fifty-seven subjects (31-49 weeks' post-menstrual age) who had an SD-OCT scan in at least 1 eye

5 cquired in their infants at 40-44 weeks post-menstrual age.

6 ssible markers of estrogen exposure, various menstrual and reproductive features, e.g., ages at menar

7 sms, family history, anthropometric factors, menstrual and/or reproductive factors, and lifestyle fac

8 mily history, height, and some components of menstrual and/or reproductive history) and modifiable fa

9 Anticoagulant-associated heavy menstrual bleeding (HMB) is an underrecognized but not u

10 investigate common pathologies such as heavy menstrual bleeding (HMB).

11 Heavy menstrual bleeding affects 25% of women in the UK, many

12 bleeding events, including 59 cases of heavy menstrual bleeding and 13 bleeding events unrelated to t

13 A 47-year-old black woman has heavy menstrual bleeding and iron-deficiency anemia.She report

14 considered a first-line treatment for heavy menstrual bleeding and should be considered, especially

15 ynaecologist for surgical treatment of heavy menstrual bleeding and who were eligible for endometrial

16 potential effect of anticoagulant therapy on menstrual bleeding at the time of treatment initiation.

17 Endometrial ablation aims to treat heavy menstrual bleeding by destroying the endometrium, which

18 51 (86%) of these heavy menstrual bleeding events (two major bleeding events, 17

19 Phenotypic stratification of UL by heavy menstrual bleeding in 3409 cases and 199,171 female cont

20 back therapy was effective in reducing heavy menstrual bleeding in women with uterine fibroids.

21 ect oral factor Xa inhibitors might increase menstrual bleeding intensity in women of reproductive ag

22 al treatment in reducing the effect of heavy menstrual bleeding on quality of life.

23 tween groups, the risk of 2 or more abnormal menstrual bleeding patterns after injury was significant

24 or progestin hormonal therapy to control the menstrual bleeding without increased risk for recurrent

25 reproductive age, are associated with heavy menstrual bleeding, abdominal discomfort, subfertility,

26 Vaginal bleeding, particularly heavy menstrual bleeding, is a common complication in women of

27 ive neoplasms that are associated with heavy menstrual bleeding.

28 n women seeking surgical treatment for heavy menstrual bleeding.

29 The main outcome of interest was menstrual blood leakage when using a menstrual cup.

30 of treatment and at least a 50% reduction in menstrual blood loss from baseline to the final month; m

31 The primary end point was menstrual blood loss of less than 80 ml during the final

32 elationship between occupational hazards and menstrual characteristics in female nurses and non-nurse

33 , occupational activities, and self-reported menstrual characteristics.

34 inflammation in patients with arthritis and menstrual cramps, but they have not provided any benefit

35 and young women, is characterized by painful menstrual cramps.

36 device was reported in 13 women who used the menstrual cup (eight in case reports, and five in one st

37 f participants wished to continue use of the menstrual cup at study completion.

38 kage, acceptability, and safety and explored menstrual cup availability to inform programmes.

39 by agencies for resource-poor settings; the menstrual cup is a less known alternative.

40 We reviewed international studies on menstrual cup leakage, acceptability, and safety and exp

41 all qualitative studies, the adoption of the menstrual cup required a familiarisation phase over seve

42 Use of the menstrual cup showed no adverse effects on the vaginal f

43 Professional assistance to aid removal of menstrual cup was reported among 47 cervical cup users a

44 We identified 199 brands of menstrual cup, and availability in 99 countries with pri

45 ive of toxic shock syndrome after use of the menstrual cup.

46 est was menstrual blood leakage when using a menstrual cup.

47 our studies made a direct comparison between menstrual cups and usual products for the main outcome o

48 Our review indicates that menstrual cups are a safe option for menstruation manage

49 nd reported leakage was similar or lower for menstrual cups than for disposable pads or tampons (n=29

50 h on experiences and leakage associated with menstrual cups, and adverse event reports.

51 nd Drug Administration for events related to menstrual cups.

52 tion on leakage, acceptability, or safety of menstrual cups.

53 t in a woman densely sampled over a complete menstrual cycle (30 consecutive days).

54 s in the follicular and luteal phases of the menstrual cycle (FDR-adjusted p-value <0.05).

55 trial days, separated by >=7 d (males) or 1 menstrual cycle (females), subjects were infused for 120

56 hat was tailored to metabolic changes of the menstrual cycle (Menstralean) or to undergo simple energ

57 men were scanned at 2 discrete phases of the menstrual cycle (midcycle and late luteal).

58 erm contraceptive in the luteal phase of the menstrual cycle also had a 3.25 times higher frequency o

59 hypothesis that hormonal fluctuations of the menstrual cycle alter sympathetic neural activity and or

60 s during hormone titer-defined phases of the menstrual cycle among 37 sex workers from Nairobi, Kenya

61 of 8 women studied during two phases of the menstrual cycle and 3 women studied during their midfoll

62 y symptoms with hormonal changes through the menstrual cycle and imply a potential for individualized

63 a diversity and inflammation (controlled for menstrual cycle and other confounders).

64 ion of hormonal signalling as a phenocopy of menstrual cycle and pregnancy-like endocrine loops and h

65 daily early morning urine samples for their menstrual cycle and up to 28 days post day of missed per

66 ory symptoms varied significantly during the menstrual cycle and were most frequent from the midlutea

67 ics and hormonal changes associated with the menstrual cycle are possible explanations for variable i

68 performance in such environments across the menstrual cycle are sparse, with mixed findings.

69 lls from women in the ovulatory phase of the menstrual cycle but not from men and identify a function

70 om the follicular to the luteal phase of the menstrual cycle by blocking the conversion of progestero

71 DTI parameters are not sensitive to menstrual cycle changes, while menopause, long-term HRT,

72 ed to target and moderate the effects of the menstrual cycle compared with the effect of simple energ

73 We assessed endometrial thickness for each menstrual cycle day (as an index of hormone regulation)

74 dings of the present study indicate that the menstrual cycle does not affect muscle sympathetic nerve

75 These results suggest that the menstrual cycle does not affect sympathetic neural activ

76 s to a greater extent than OCP usage and the menstrual cycle does.

77 based therapies and should be tracked in the menstrual cycle during the course of PTSD treatment.

78 r (PMDD) when given daily or for half of the menstrual cycle during the luteal phase.

79 ption, reproductive hormones, and markers of menstrual cycle dysfunction including sporadic anovulati

80 iated with reduced testosterone and improved menstrual cycle function in healthy premenopausal women.

81 e associations between caffeine exposure and menstrual cycle function, and we are aware of no previou

82 appear to have adverse short-term effects on menstrual cycle function, including sporadic anovulation

83 ssess RR of cycle-average alcohol intake and menstrual cycle function.

84 own between cycle-average alcohol intake and menstrual cycle function.

85 human papillomavirus (HPV) DNA detection and menstrual cycle has been inconsistent.

86 varian follicles to produce the human 28-day menstrual cycle hormone profile, which controls human fe

87 ariations in respiratory symptoms during the menstrual cycle in a general population, and potential m

88 in the follicular phase (day 3) of the last menstrual cycle in all women.

89 nd lesions vary according to the week of the menstrual cycle in benign but not in malignant lesions.

90 HSV entry receptor expression throughout the menstrual cycle in genital tissues was performed, and th

91 als, SHIV infections occurred earlier in the menstrual cycle in STI-positive macaques (P = .01, by th

92 underlying blood pressure control across the menstrual cycle in women with POTS are unknown.

93 mptoms of orthostatic intolerance across the menstrual cycle in women with POTS.

94 mptoms of orthostatic intolerance across the menstrual cycle in women with POTS.

95 Hormonal fluctuations during the menstrual cycle influence energy intake and expenditure

96 The menstrual cycle is characterized by predictable patterns

97 elia during a mouse estrous cycle or a human menstrual cycle is presently unknown.

98 [4.00] years and 13 women with no change in menstrual cycle length with a mean [SD] age of 44.92 [2.

99 41] years; including 14 women with change in menstrual cycle length with a mean [SD] age of 45.50 [4.

100 for perimenopause, which is mainly based on menstrual cycle length, was not associated with MAO-A VT

101 tion as against single ovulation in a normal menstrual cycle makes the procedure dependent on several

102 ravings and metabolic changes throughout the menstrual cycle may increase weight loss above that achi

103 onadal hormones, especially estrogen, in the menstrual cycle may play a critical role in fear extinct

104 teroid levels during the luteal phase of the menstrual cycle may precipitate affective symptoms.

105 to achieve contraception within our previous menstrual cycle models.

106 omen, one in two of such women believe their menstrual cycle negatively impacts training and performa

107 eveloped to model hormonal regulation of the menstrual cycle of a woman from age 20 to 51.

108 estrus but not in the diestrus stage of the menstrual cycle of females was inhibited by pioglitazone

109 After one menstrual cycle of single-blind placebo, participants we

110 nd postmenstrual age (the age since the last menstrual cycle of the mother) from longitudinal recordi

111 age 18-50 years; 115 male and 45 female) and menstrual cycle phase (29 follicular and 16 luteal) effe

112 on of sleep and waking while controlling for menstrual cycle phase and hormonal contraceptive use.

113 Menstrual cycle phase does not appear to affect exercise

114 cal confirmation of overnight abstinence and menstrual cycle phase, analyses were performed to compar

115 with genital antiretroviral concentrations, menstrual cycle phase, bacterial vaginosis, genital blee

116 se in well-trained women are not affected by menstrual cycle phase, but differ between dry and humid

117 Our data show menstrual cycle phase-associated changes in both endocer

118 essions occurring during hormonally distinct menstrual cycle phases.

119 ar menstrual cycle, undergoing treatment for menstrual cycle regularity shortly after menarche, havin

120 Menstrual cycle status was based on the last menstrual p

121 trated that a small endogenous rhythm of the menstrual cycle still affects T(core) and also that chro

122 ns proposed that an endogenous rhythm of the menstrual cycle still occurs with OCP usage.

123 In a human menstrual cycle the endometrium undergoes remodeling, sh

124 Normal menstrual cycle variations in cortical excitability are

125 The follicular phase of the menstrual cycle was associated with an elevated CCL2 lev

126 Regular menstrual cycle was reported by more than 90% of female

127 Significant rhythmic variations over the menstrual cycle were found in each symptom for all subje

128 Genital secretions and tissues during the menstrual cycle were studied.

129 d as resumed by the occurrence of at least 1 menstrual cycle), pregnancies, and disease-free survival

130 bility (probability of conception in a given menstrual cycle).

131 between diets (and low hormone phase of the menstrual cycle).

132 Over one menstrual cycle, 20 human immunodeficiency virus (HIV)-i

133 were detected during the luteal phase of the menstrual cycle, and longitudinal analysis showed the fr

134 uish the follicular and luteal phases of the menstrual cycle, and phases were confirmed by hormone me

135 men included in this review are pain and the menstrual cycle, contraception, and preconception counse

136 en concentrations fluctuate over the estrous/menstrual cycle, dynamically modulating estrogen recepto

137 resses genital virus shedding throughout the menstrual cycle, even in the presence of factors reporte

138 ncy virus (SHIV) susceptibilities during the menstrual cycle, likely caused by cyclic variations in i

139 patterns of reproductive hormones across the menstrual cycle, particularly ultradian rhythms, are wel

140 human endometrial transformation across the menstrual cycle, providing insights into this essential

141 metrium at single-cell resolution across the menstrual cycle, resolving cellular heterogeneity in mul

142 Hormone parameters, menstrual cycle, symptoms of hypogonadism, and offspring

143 ity to HIV during the secretory phase of the menstrual cycle, the molecular mechanisms involved remai

144 between thyroid cancer and having irregular menstrual cycle, undergoing treatment for menstrual cycl

145 he endogenous fluctuation in E(2) during the menstrual cycle, we conducted a within-person repeated-m

146 This could be the case during the menstrual cycle, when using hormone-based birth control,

147 breast DTI is not restricted throughout the menstrual cycle, whereas the modulations in diffusion pa

148 eatability, remaining almost equal along the menstrual cycle, with a low mean within-subject coeffici

149 V/SHIV has been recently associated with the menstrual cycle, with particular susceptibility observed

150 s relatively stable during this stage of the menstrual cycle, with small-scale changes affecting 5% o

151 cise performance is not different across the menstrual cycle, yet is lower in humid heat, in conjunct

152 anscranial magnetic stimulation to determine menstrual cycle-related changes in cortical excitability

153 Menstrual cycle-specific estimates of urinary BPA and ph

154 endometrial methylome changes throughout the menstrual cycle.

155 ercising in dry and humid heat, across their menstrual cycle.

156 from women with endometriosis throughout the menstrual cycle.

157 tissue going through remarkable changes each menstrual cycle.

158 pre-receptive and receptive phase within one menstrual cycle.

159 ing the follicular and luteal phases of each menstrual cycle.

160 from three specimens spaced throughout each menstrual cycle.

161 ding and 13 bleeding events unrelated to the menstrual cycle.

162 he progesterone-dominant luteal phase of the menstrual cycle.

163 tenuated by hormonal fluctuations within the menstrual cycle.

164 cular (EF) and mid-luteal (ML) phases of the menstrual cycle.

165 ions in orthostatic tolerance throughout the menstrual cycle.

166 tic symptoms in the late luteal phase of the menstrual cycle.

167 erwent imaging weekly, four times during one menstrual cycle.

168 enital than plasma concentrations across the menstrual cycle.

169 to oocytes or matured follicles in a single menstrual cycle.

170 e expressed in all tissues during the entire menstrual cycle.

171 trols, matched with respect to age, sex, and menstrual cycle.

172 yclicity of cortical excitability across the menstrual cycle.

173 n the kinetic parameters and the week of the menstrual cycle.

174 follicular and (2) mid luteal phases of the menstrual cycle.

175 rease during the high-fertility phase of the menstrual cycle.

176 t and HIV risk in sex workers with a natural menstrual cycle.

177 from Western New York were followed for </=2 menstrual cycles (2005-2007) and provided fasting blood

178 trial cancer, we created the total number of menstrual cycles (TNMC) that a woman experienced during

179 st-morning urine specimens during one to two menstrual cycles and male partners collected specimens d

180 equired a familiarisation phase over several menstrual cycles and peer support improved uptake (two s

181 gh it is well established that the number of menstrual cycles and pregnancy (in this case transiently

182 articipants (n = 259) were followed for </=2 menstrual cycles and provided fasting blood specimens </

183 No or irregular maternal menstrual cycles before pregnancy were associated with h

184 s (mean age 24.3 +/- 4.9 years) with regular menstrual cycles between 23 and 35 days.

185 The regularity of menstrual cycles is one of the important indicators of f

186 1650 women with regular menstrual cycles undergoing their first cycle of in-vitr

187 Six healthy women with regular menstrual cycles were administered the NKB antagonist AZ

188 cesses, such as cell cycle, circadian clock, menstrual cycles, are governed by oscillatory systems co

189 were randomized to receive, for the next two menstrual cycles, either double-blind placebo or dutaste

190 matase inhibitors on the dynamics of women's menstrual cycles.

191 A total of 221 participants contributed 706 menstrual cycles.

192 olled, cross-over trials, each lasting three menstrual cycles.

193 ued until the first few days of menses for 6 menstrual cycles.

194 western New York State, were followed for 2 menstrual cycles.

195 ar, ovulatory and mid-luteal phases of their menstrual cycles.

196 s simplex virus type 2 coinfection, during 2 menstrual cycles.

197 d with placebo plus folic acid for up to six menstrual cycles; for women who conceived, study treatme

198 the BioCycle Study were followed for up to 2 menstrual cycles; they provided fasting blood specimens

199 reased by about 2.5% for every additional 10 menstrual-cycles.

200 2 expression, which persisted independent of menstrual cycling.

201 moderately associated with the occurrence of menstrual disorder (OR > 1).

202 nts was the most significant risk factor for menstrual disorders (OR = 1.53, 95% CI: 1.39-1.68), foll

203 revealed the significant association between menstrual disorders and occupational hazards among femal

204 he association of occupational exposures and menstrual disorders is scarce.

205 demonstrated that 41% of nurses experienced menstrual disorders.

206 s population and reliance on self-report for menstrual disturbances and LEA.

207 rplay between low energy availability (LEA), menstrual disturbances, and decreased bone mineral densi

208 e to sexual side effects (e.g., infertility, menstrual disturbances, and impotence).

209 rajectories indicates that participants with menstrual dysfunction might have decreased adaptive resp

210 articipants by their energy availability and menstrual dysfunction status.

211 mouse model of endometriosis using syngeneic menstrual endometrial tissue introduced into the periton

212 Menstrual experience included multiple themes: menstrual

213 odel maps distal and proximal antecedents of menstrual experience through to the impacts of this expe

214 h synthesis of extant qualitative studies of menstrual experience, we highlight consistent challenges

215 ationships to develop a directional model of menstrual experience.

216 llenges and developed an integrated model of menstrual experience.

217 intrauterine system, tranexamic acid (during menstrual flow), high-dose progestin-only therapy, or co

218 l pain during menstruation along with normal menstrual flow.

219 ns, including young healthy women with heavy menstrual flow.

220 s ranging from primary amenorrhea to loss of menstrual function prior to age 40.

221 Reflecting the focus of menstrual health research globally, there was an absence

222 had complete treatment exposure and adequate menstrual history (including age at menarche, current me

223 ted but important connection between FGS and menstrual hygiene initiatives in Africa is highlighted.

224 Differing approaches to menstrual hygiene management (MHM) have been associated

225 nal mass, obstructive uropathy, infertility, menstrual irregularities and abnormal renal function tes

226 tus, number of live births, age at menarche, menstrual irregularity, age at first birth, stillbirths,

227 , gonadal failure, erectile dysfunction, and menstrual issues in SCD.

228 ron-deficiency anaemia (IDA) attributable to menstrual losses and limited iron intake.

229 environment restricting access to affordable menstrual materials.

230 Attention to women's and girls' menstrual needs is critical for global health and gender

231 Our findings demonstrate menstrual pain's association with abnormal autonomic act

232 Menstrual pain, also known as dysmenorrhea, is a leading

233 ve important health implications, monitoring menstrual patterns after concussion may be warranted in

234 may have increased risk of multiple abnormal menstrual patterns after concussion.

235 Brain injury may interrupt menstrual patterns by altering hypothalamic-pituitary-ov

236 Because abnormal menstrual patterns can have important health implication

237 n, 16 (23.5%) experienced 2 or more abnormal menstrual patterns during the study period compared with

238 messages received by patients, yielding 487 menstrual patterns in 128 patients (mean [SD] age, 16.2

239 To compare abnormal menstrual patterns in adolescent and young women after a

240 evaluate the association of concussion with menstrual patterns in young women.

241 luteinizing hormone and added information on menstrual patterns to determine menopausal status using

242 Menstrual patterns were assessed using a weekly text mes

243 Abnormal menstrual patterns were defined by an intermenstrual int

244 Early age at the natural final menstrual period (FMP) or menopause has been associated

245 m 10 years before to 8 years after the final menstrual period (FMP), with a decrease of approximately

246 ) a validated algorithm to estimate the last menstrual period (LMP), 2) LMP + 14 days (i.e., concepti

247 tarted 3-drug ART regimens before their last menstrual period and did not switch or stop ART in pregn

248 cipants who had reliable information on last menstrual period and gestational age confirmed by crown-

249 d between the first day of the last maternal menstrual period and the time at imaging) using a handhe

250 n in which seizures are clustered around the menstrual period associated with neurosteroid withdrawal

251 gnancy, defined as the first day of the last menstrual period before conception.

252 eing severe or bothersome, who had not had a menstrual period for at least 12 months, and who had not

253 l age more accurately than it predicted last menstrual period gestational age.

254 rongly associated with methylation than last menstrual period gestational age.

255 Her last menstrual period occurred 2 weeks prior to presentation.

256 s in CVD risk factors before and after final menstrual period or surgery.

257 ing the period from 3 months before the last menstrual period through 1 month after delivery and thei

258 in Medicaid from 3 months before their last menstrual period through at least 1 month after delivery

259 During the last menstrual period to 90 days postpartum, 56% of women wit

260 birth, and adverse conditions from the last menstrual period to 90 days postpartum.

261 The median age (Q1, Q3) at the final menstrual period was 48 (45, 51) years when described am

262 ng WWH with surgical menopause, age at final menstrual period was summarized for postmenopausal WWH (

263 Having a higher income and regular menstrual period were negatively associated with lower u

264 y pregnancy loss (within 6 weeks of the last menstrual period) among women attempting pregnancy.

265 icular or luteal phase using days since last menstrual period, and analyzed by tandem mass spectromet

266 ly healthy, within three years of their last menstrual period, and free of current or past CV disease

267 demographic characteristics, season of last menstrual period, apparent temperature, air basin of mot

268 iving in the same residence since their last menstrual period, in households served by a private wate

269 tionally used to compare ultrasound and last menstrual period-based gestational age predictions.

270 computed using both ultrasound and the last menstrual period.

271 s were 52.6 y old, and 1.4 y past their last menstrual period.

272 Menstrual cycle status was based on the last menstrual period.

273 s (n = 87; ages 18-40 years) during both the menstrual phase (MP; cycle day 1-2; low E+), and the fol

274 trations were significantly increased during menstrual phase and 24 h post-progesterone-withdrawal re

275 ic and autonomic differences associated with menstrual phase and dry vs. humid heat.

276 forearm blood flow differed as a function of menstrual phase and environment (interaction: P </= 0.01

277 ll-trained women exercising in the heat: (1) menstrual phase did not affect performance, (2) humidity

278 A growing literature indicates sex and menstrual phase differences in responses to nicotine.

279 The aim of this study was to assess sex and menstrual phase influences on a broad range of measures

280 onfounders, like, for example, hunger state, menstrual phase, and BMI, as well as how to optimally ma

281 When adjusted for menstrual phase, the association between P. amnii and TV

282 8 to 35 y, were seen during their follicular menstrual phase.

283 Data were unaffected by menstrual phase.

284 Mean skin temperature did not differ between menstrual phases (P >/= 0.13) but was higher in DRY than

285 in human endometrium from late secretory and menstrual phases.

286 ate mechanisms responsible for regulation of menstrual physiology and to investigate common pathologi

287 nstrual experience included multiple themes: menstrual practices, perceptions of practices and enviro

288 d women need effective, safe, and affordable menstrual products.

289 and environmental effect comparing different menstrual products.

290 Mothers who took a menstrual regulation supplement were more likely than mo

291 ithout cleft palate (CL +/- P) risk and that menstrual regulation supplements would increase CL +/- P

292 model of menstruation, validating its use in menstrual research.

293 The 5-year cumulative incidence estimate of menstrual resumption was 72.6% (95% CI, 65.7%-80.3%) amo

294 P axis in endometriosis patients compared to menstrual stage matched healthy fertile controls in hope

295 The quantitative BEC was associated with the menstrual status (BEC in premenopausal women, 31.48 +/-

296 history (including age at menarche, current menstrual status, age at last menstruation, and menopaus

297 The sociocultural context, including menstrual stigma and gender norms, influenced experience

298 n several, androgen excess and cutaneous and menstrual symptoms.

299 2,463 age-matched comparison women with few menstrual symptoms.

300 Menstrual toxic shock syndrome (mTSS) is a life-threaten